

In the Claims:

1-26. **(Canceled)**

27. **(Currently Amended)** A molecular conjugate comprising a human monoclonal antibody that binds to the human macrophage mannose receptor dendritic cells linked to an antigen.

28. **(Original)** The molecular conjugate of claim 27, wherein the antigen comprises a component of a pathogen.

29. **(Original)** The molecular conjugate of claim 27, wherein the antigen comprises a tumor antigen or an autoantigen.

30. **(Original)** The molecular conjugate of claim 27, wherein the antibody portion of the conjugate comprises an antibody fragment or a single chain antibody.

31. **(Currently Amended)** ~~The molecular conjugate of claim 27~~ A molecular conjugate comprising a human monoclonal antibody that binds to human dendritic cells linked to an antigen, wherein the antibody comprises heavy chain and light chain variable regions which comprise the amino acid sequences shown in SEQ ID NO:2 and SEQ ID NO:4, respectively, and conservative sequence modifications thereof.

32. **(Original)** The molecular conjugate of claim 27, wherein the antigen is a melanoma associated antigen selected from the group consisting of Gp100 and Pmel-17.

33. **(Currently Amended)** A molecular conjugate comprising a human monoclonal antibody that binds to the human macrophage mannose receptor dendritic cells linked to Pmel-17 antigen.

34. **(Original)** The molecular conjugate of claim 33, wherein the antibody comprises heavy chain and light chain variable regions which comprise the amino acid sequences shown in SEQ ID NO:2 and SEQ ID NO:4, respectively, and conservative sequence modifications thereof.

35. **(Original)** The molecular conjugate of claim 33, encoded by the nucleotide sequence shown in SEQ ID NO:8.

36-37. **(Canceled)**

38. **(Currently Amended)** A composition comprising a molecular conjugate according to claim 27, 31 or 33 and a pharmaceutically acceptable carrier.

39. **(Original)** The composition of claim 38 further comprising an adjuvant.

40-41. **(Canceled)**

42. **(Currently Amended)** A method for targeting an antigen to a dendritic cell in a subject comprising administering to the subject the a composition according to claim 38.

43. **(Currently Amended)** A method of inducing or enhancing an immune response against an antigen in a subject comprising administering to the subject the a composition according to claim 38.

44. **(Original)** The method of claim 43, wherein the immune response comprises presentation of the antigen as a component of an MHC-I or MHC-II conjugate.

45. **(Original)** A method of immunizing a subject comprising administering to the subject the composition according to claim 38.

46. **(Original)** The method of claim 45, wherein the composition is administered in an amount sufficient to induce cytokine release by dendritic cells.

47-48. **(Canceled)**

49. (New) The molecular conjugate of claim 27, wherein the antibody comprises heavy chain and light chain variable regions which comprise the amino acid sequences shown in SEQ ID NO:2 and SEQ ID NO:4, respectively.

50. (New) The molecular conjugate of claim 27, wherein the antigen is a melanoma associated antigen selected from the group consisting of Gp100 and Pmel-17.

51. (New) The molecular conjugate of claim 27, wherein the receptor comprises the amino acid sequence shown in SEQ ID NO:7.